Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03022318Phase 2Completed

Carbidopa-levodopa in Neovascular AMD

Role: lead

NCT03197493Phase 2Completed

Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

Role: lead

NCT03023059Phase 2Completed

Dose Ranging Study of Carbidopa-levodopa

Role: lead

NCT03451500Phase 2Terminated

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Role: lead

NCT02873351Phase 2Withdrawn

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

Role: lead

All 5 trials loaded